

**Emily E. Hartwell, PhD**  
Crescenz Veteran Affairs Medical Center  
University of Pennsylvania  
Email: Emily.Hartwell@penmedicine.upenn.edu

---

## EDUCATION

---

- 2012-2018 **University of California, Los Angeles**, Los Angeles, CA  
*Ph.D. in Clinical Psychology*  
*Minor in Quantitative Methods*  
Dissertation Title: Alcohol craving: Clinical, assessment, & genetic considerations  
Committee Chair: Lara Ray, PhD  
Committee Members: Drs. Steve Lee, Alicia Izquierdo, Christine Grella
- 2017-2018 **West Los Angeles Veterans Affairs**, Los Angeles, CA  
*Predoctoral Psychology Clinical Internship*  
Director of Training: Anna Okonek, PhD
- 2012-2014 **University of California, Los Angeles**, Los Angeles, CA  
*M.A. in Clinical Psychology*  
Master's Thesis: Pharmacogenetics of naltrexone and varenicline in heavy drinking smokers  
Committee Chair: Lara Ray, PhD  
Secondary Advisor: David Jentsch, PhD
- 2004-2008 **North Carolina State University**, Raleigh, NC  
*B.A. in Political Science, Cum Laude*  
Completed University Honors Program  
Minors: Microbiology and Spanish
- 

## PROFESSIONAL APPOINTMENTS

---

- 2022-present **Research Psychologist**  
Crescenz Veterans Affairs Medical Center
- 2022-present **Assistant Professor**  
Department of Psychiatry  
Perelman School of Medicine, University of Pennsylvania
- 2021-2022 **Office of Research & Development/Mental Health Liaison**  
Office of Research & Development  
Veterans Affairs
- 2018-2021 **Postdoctoral Fellow**  
Crescenz Veterans Affairs Medical Center, Philadelphia, PA  
University of Pennsylvania  
Mentor: Henry Kranzler, MD
- 

## LICENSURE

---

Pennsylvania Psychology Board  
License conferred: 12/2/2022  
Renewal: October 2025

---

HONOR & AWARDS

---

2024	<b>Outstanding Field Editor</b> , <i>Alcohol: Clinical and Experimental Research</i>
2023	<b>Mack Institute Technology Fellow</b> , Wharton Business School, University of Pennsylvania
2022	<b>NIAAA Junior Investigator Award</b> to attend the annual Research Society on Alcoholism meeting
2021	<b>Early Career Investigator Award</b> to attend the annual World Congress of Psychiatric Genetics
2021	<b>Margaret 'Emily' Gere Book Award</b> , VA Advanced Fellowship
2013-2017	<b>Student Merit Award</b> , Research Society on Alcoholism
2012-2017	<b>UCLA Psychology Department Travel Award</b> (award each year)
2015	<b>NIDA Women and Sex/Gender Differences Junior Investigator Travel Award</b> to attend the annual College on Problems of Drug Dependence meeting
2013	<b>Graduate Summer Research Mentorship Award</b> , UCLA Graduate Division
2012-2013	<b>Distinguished University Fellowship</b> , UCLA Graduate Division
2011	<b>NIAAA/NIDA Early Career Investigator Travel Award</b> to attend the annual meeting of the American Psychological Association
2010	<b>Summer Research Fellow</b> , NIDA-sponsored Drug Abuse Research Training (DART) Program, Medical University of South Carolina (MUSC)
2004-2008	<b>Dean's List</b> , NC State University
2007	Member, <b>Pi Sigma Alpha</b> , Political Science Honor Society, NC State University
2005	<b>First Year College Scholarship</b> , NC State University

---

GRANT SUPPORT

---

Current

1 IK2 CX002336-01A2	Hartwell (PI)	08/2022-07/2027
Department of Veterans Affairs		
<i>Genetic architecture of substance use disorders and major depression</i>		
Mentors: Drs. Henry Kranzler, David Oslin, Joel Gelernter, & Benjamin Voight		
Total Cost: \$985,674.00 (100% Effort)		
Alkermes Investigator Initiated Award	Kranzler (PI)	04/2022-06/2025
Alkermes Biopharmaceutical Company		
<i>Testing the reward-drinker hypothesis of naltrexone using an extended-release formulation</i>		
Role: Co-investigator		
Total Cost: \$300,000 (Effort subsumed under IK2)		
P30 DA046345	Durbroff (PI)	05/2023-present
<i>Pilot Study of a Multi-System Analysis of Opioid Receptor Binding</i>		
Role: Co-investigator (Effort subsumed under IK2)		

Completed

VA MIRECC Pilot	Hartwell (PI)	09/2019-10/2020
<i>Pharmacogenetics of buprenorphine response in Veterans being treated for opioid use disorder</i>		
Mentors: Drs. Henry Kranzler, Kyle Kampman, Richard Crist		
Role: Principal investigator		
Total cost: \$25,000		
T32 DA07272-21	Grella (PI)	07/2013-06/2016

National Institute on Drug Abuse  
*Integrated Substance Abuse Programs (ISAP)*  
Role: Predoctoral Research Fellow  
Mentors: Drs. Lara Ray, Suzette Glasner-Edwards, Mitch Karno

---

#### OTHER SIGNIFICANT PROJECTS

---

*A retrospective study of topiramate pharmacotherapy in Veterans: Effects on heavy drinking and risks of adverse drug events*

Hartwell (Project PI) 06/2022-10/2023

Non-funded project to examine the efficacy of topiramate in Veterans using VINCI data  
Crescenz VA Medical Center

---

#### PEER REVIEWED PUBLICATIONS ([GOOGLE SCHOLAR](#) | [ORCID](#))

---

1. Clarke, S.,\* **Hartwell, E.E.**,\* Choi, D.-S.,\* Krystal, J.,\* Messing, R.O.,\* Ferguson, L.B. (in press) Next generation biomarkers for AUD diagnosis, prognosis, and treatment: A critical review. *Alcohol: Clinical and Experimental Research*
2. **Hartwell, E.E.**, Jinwala, Z., Milone, J.,<sup>†</sup> Ramirez, S.,<sup>†</sup> Gelernter, J., Kranzler, H.R., Kember, R.L. (in press) Application of polygenic scores to a deeply phenotyped sample enriched for substance use disorders reveals extensive pleiotropy with psychiatric and medical traits. *Neuropsychopharmacology*
  - a. *MedRxiv*, <https://doi.org/10.1101/2024.01.22.24301615>
3. **Hartwell, E.E.**,\* Schwandt, M.,\* Nunez, Y.Z., Wetherill, R.R., Kember, R.L., Wiers, C.E., Gelernter, J., Kranzler, H.R. (2024) Identifying neurofunctional domains across substance use disorders. *The American Journal of Drug and Alcohol Abuse*, 50(4), 536-546.
4. Kranzler, H.R., Feinn, R., Jinwala, Z., Khan, Y.,<sup>†</sup> Davis, C.N., Oikonomou, A.,<sup>†</sup> Silva-Lopez, D.,<sup>†</sup> Burton, I.,<sup>†</sup> Dixon, M.,<sup>†</sup> Milone, J.,<sup>†</sup> Ramirez, S.,<sup>†</sup> Shifman, N.,<sup>†</sup> Gelernter, J., **Hartwell, E.**, Kember, R.L. (2024) Genetic risk moderates mediated associations between adverse childhood events, mood and anxiety disorders, and substance dependence. *Nature Human Behavior*, 8, 1616-1627.
  - a. *MedRxiv*, <https://doi.org/10.1101/2023.10.24.23297419>
5. Toikumo, S., Vickers-Smith, R.A., Jinwala, Z., Zu, H., Saini, D., **Hartwell, E.E.**, Venegas, M.V.P., Sullivan, K., Xu, K., Jacobson, D.A., Gelernter, J., Rentsch, C.T., Stahl, E., Cheatle, M., Zhou, H.T., Waxman, S., Justice, A.C., Kember, R.L., & Kranzler, H.R. (2024) The genetic architecture of pain intensity in a sample of 598,339 US Veterans. *Nature Medicine*, 30(4), 1075-1084.
  - a. *MedRxiv*, <https://doi.org/10.1101/2023.03.09.23286958>
6. Kranzler, H.R., & **Hartwell, E.E.** (2023) Medications for treating alcohol use disorder: A narrative review. *Alcohol: Clinical and Experimental Research*, 47(7), 1224-1237.
7. Kranzler, H.R., Feinn, R., Xu, H., Ho, B.L.,<sup>†</sup> Saini, D.,<sup>†</sup> Nicastro, O.,<sup>†</sup> Jacoby, A.,<sup>†</sup> Toikumo, S., Gelernter, J., **Hartwell, E.E.**, & Kember, R.L. (2023) Polygenic risk for substance-related traits predicts substance use onset and progression: Sex and population group differences. *Addiction* 119(9), 1675-1686.
  - a. *MedRxiv*, <https://doi.org/10.1101/2022.09.29.2228047>
8. Vickers-Smith, R., Justice, A.C., Becker, W., Rentsch, C.T., Curtis, B., **Hartwell, E.E.**, Kember, R.L., Tate, J., & Kranzler, H.R. (2023) Racial and ethnic disparities in alcohol use disorder diagnoses in a nationwide longitudinal cohort study of 700,013 US Veterans. *American Journal of Psychiatry*, 180(6), 426-436.

- a. *medRxiv*. DOI: 10.1101/2021.07.14.21256113
9. Naps, M., Chen, S., **Hartwell, E.E.**, Rentsch, C., Kranzler, H.R. (2023) Effects of topiramate therapy on serum bicarbonate concentration in a sample of 10,279 Veterans. *Alcohol: Clinical and Experimental Research*, 47(3), 438-447.
  10. Kember, R.L.\*, **Hartwell, E.E.\***, Xu, H., Rotenberg, J., Almasy, L., Zhou, H., Gelernter, J., & Kranzler, H.R. (2023) Phenome-wide association analysis of substance use disorders in a deeply phenotyped sample. *Biological Psychiatry*, 93(6), 536-545.
    - a. *medRxiv*, DOI: 10.1101/2022.02.09.22270737
  11. Kember, R.L., Vickers-Smith, R.A., Xu, H., Toikumo, S., Niarchou, M., Zhou, H., **Hartwell, E.E.**, Crist, R.C., Rentsch, C.T., Davis, L.K., Kampman, K., & Justice, A.C. (2022) Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci with predominant effects on brain. *Nature Neuroscience*, 25, 1279-1287.
    - a. *medRxiv*. DOI: 10.1101/2021.12.13.21267480
  12. Kranzler, H.R., Chen, S., Naps, M., **Hartwell, E.E.**, Fiellin, D., & Rentsch, C. (2022) Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data. *Addiction*, 117(11), 2826-2836.
    - a. *medRxiv*. DOI: 10.1101/2022.05.17.22275219
  13. Love, T., Shabalin, A., Kember, R., Docherty, A., Zhao, H., Gelernter, J., Dubroff, J., **Hartwell, E.**, Zubieta, J-K., & Kranzler, H.R. (2022) Unique and joint associations of polygenic risk for major depression and opioid use disorder with endogenous opioid system function. *Neuropsychopharmacology*, 47, 1784-1790.
  14. Livne, O., Feinn, R., Knox, J., **Hartwell, E.E.**, Hasin, D., Gelernter, J., Kranzler, H.R. (2022) Alcohol withdrawal: Prevalence, characteristics, and risk factors in the National Epidemiological Survey on Alcohol and Related Conditions-III. *Alcohol: Clinical and Experimental Research*, 46(3), 422-433.
  15. Kranzler, H.R., Witkiwitz, K., Pond, T., **Hartwell, E.E.**, Gelernter, J., Crist, R.C., Feinn R. (2022) Post-treatment effects of topiramate on heavy drinking: A combined analysis of two placebo-controlled trials. *Addiction Biology*, 27(2), e13130.
  16. **Hartwell, E.E.**, Merikangas, A., Verma, S., Ritchie, M., Regeneron Genetics Center, Kranzler, H.R., & Kember, R.L. (2022) Genetic liability for substance use associated with medical comorbidities in electronic health records of African- and European-ancestry individuals. *Addiction Biology*, 27(1), e13099.
  17. Crist, R., Vicker-Smith, R., Kember, R.L., Rentsch, C.T., Edelman, E.J., **Hartwell, E.E.**, Kampman, K., Kranzler, H.R. (2021) Analysis of genetic and clinical factors associated with buprenorphine response. *Drug and Alcohol Dependence*, 227, 109013.
  18. **Hartwell, E.E.**, Feinn, R., Witkiwitz, K., Pond, T., & Kranzler, H.R. (2021) World Health Organization risk drinking levels as a treatment outcome measure in topiramate trials. *Alcohol: Clinical and Experimental Research*, 45(8), 1664-1671.
  19. Kranzler, H.R., **Hartwell, E.E.**, Feinn, R., Pond, T., Witkiwitz, K., Gelernter, J., Crist, R.C. (2021) Combined analysis of the moderating effect of GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder. *Drug and Alcohol Dependence*, 225, 108762.
  20. Ray, L.A., Green, R., Leventhall, A.M., Grodin, E.N., Enders, C., Li, G., Lim, A., **Hartwell, E.**, Venegas, A., Meredith, L., Nieto, S.J., Shoptaw, S., & Miotto, K. (2021) Efficacy of combining varenicline and naltrexone for smoking cessation and drinking reduction: A randomized clinical trial. *American Journal of Psychiatry*, 178(9), 818-828.

21. Kranzler, H.R., Morris, P.E., Pond, T., Crist, R., Kampman, K.M., **Hartwell, E.E.**, Lynch, K. (2021) Prospective pharmacogenetic study of topiramate for treating alcohol use disorder. *Neuropsychopharmacology*, *46*(8), 1407-1413.
22. Green, R., MacKillop, J., **Hartwell, E.E.**, Lim, A.C., Bakersfield, W., Karno, M., & Ray, L.A. (2021) Behavioral economic demand for alcohol and cigarettes in heavy drinking smokers: Cross-substance relationships. *Nicotine & Tobacco Research*, *23*(4), 748-755.
23. Kranzler, H.R., Lynch, K., Crist, R., **Hartwell, E.E.**, Le Moigne, A., Laffont, C., & Andorn, A. (2021) A delta-opioid receptor gene polymorphism moderates the therapeutic effect of extended-release buprenorphine in opioid use disorder. *International Journal of Neuropsychopharmacology*, *24*(2), 89-96.
24. **Hartwell, E.E.**, Feinn, R., Morris, P., Gelernter, J., Krystal, J., Arias, A.J., Oslin, D., Schacht, J.P., Hoffman, M., Petrakis, I., Gueorguieva, R., Anton, R.F., & Kranzler, H. (2020). Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on naltrexone treatment of alcohol use disorder. *Addiction*, *115*(8), 1426-1437.
25. Ehrie, J.M., **Hartwell, E.E.**, Morris, P., Mark, T.L., & Kranzler, H.R. (2020) Addiction specialists' opinions about medications for treating alcohol use disorder. *Frontiers in Psychiatry*, *11*, 47.
26. **Hartwell, E.E.**, Bujarski, S., Green, R., & Ray, L.A. (2019) Convergence between the Penn Alcohol Craving Scale and diagnostic interview for the assessment of alcohol craving. *Addictive Behaviors Reports*, *10*, 1000198.
27. Kranzler, H.R., Feinn, R., Morris, P.M., & **Hartwell, E.E.** (2019) A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. *Addiction*, *114*, 1547-1555.
28. **Hartwell, E.E.**, & Kranzler, H.R. (2019) Pharmacogenetics of alcohol use disorder treatments: An update. *Expert Opinion on Drug Metabolism & Toxicology*, *15*(7), 553-564.
29. Lim, A.C., Ray, L.A., Green, R., Roche, D.J.O., Bujarski, S., **Hartwell, E.E.**, Rohrbaugh, T., Ghahremani, D., Hutchison, K.E., & Miotto, K. (2019) Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent. *Drug and Alcohol Dependence*, *200*, 181-190.
30. Roche, D.J.O., Bujarski, S., Green, R., **Hartwell, E.E.**, Leventhal, A.M., & Ray, L.A. (2019). Alcohol and tobacco consumption is associated with increased odds of same day marijuana use. *Drug and Alcohol Dependence*, *200*, 40-49.
31. Ray, L.A., Bujarski, S., Grodin, E., **Hartwell, E.**, Green, R., Venegas, A., Lim, A.C., Gillis, A., & Miotto, K. (2019). State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. *The American Journal of Drug and Alcohol Abuse*, *45*(2), 124-140.
32. **Hartwell, E.E.**, & Ray, L.A. (2018) Relationship between tonic and phasic craving for alcohol. *Addictive Behaviors Reports*, *7*, 71-74.
33. Ray, L.A., Green, R., Roche, D.J.O., Bujarski, S., **Hartwell, E.E.**, Lim, A.C., Rohrbaugh, T., Ghahremani, D., Hutchison, K.E., & Miotto, K. (2018) Pharmacogenetic effects of naltrexone in individuals of East Asian descent: Human laboratory findings from a randomized trial. *Alcohol: Clinical and Experimental Research*, *42*(3), 613-623.
34. **Hartwell, E.E.**, & Ray, L.A. (2017) Craving as a DSM-5 symptom of alcohol use disorder in non-treatment seekers. *Alcohol and Alcoholism*, *53*(3), 235-240.

35. Ray, L.A., Bujarski, S., Yardley, M., Roche, D.J.O., & **Hartwell, E.E.** (2017) Differences between treatment-seeking and non-treatment seeking participants in medication studies for alcoholism: Do they matter? *American Journal of Drug and Alcohol Abuse*, 43(6), 703-710.
36. **Hartwell, E.E.**, Moallen, N., Courtney, K.E., Glasner-Edwards, S., & Ray, L.A. (2016) Gender differences in the association of internalizing symptoms and craving in methamphetamine users. *Journal of Addiction Medicine*, 10(6), 395-401.
37. Glasner-Edwards, S., **Hartwell, E.E.**, Mooney, L., Garneau, H.C., Brecht, M.-L., Rawson, R. (2016) Changes in stress reactivity among stimulant dependent adults after treatment with mindfulness based relapse prevention. *Journal of Addiction Research and Therapy*, 7(5), 13-19.
38. Glasner-Edwards, S., Mooney, L.J., Ang, A., Garneau, H.C., **Hartwell, E.E.**, Brect, M.-L., & Rawson, R.A. (2016) Mindfulness based relapse prevention for stimulant dependent adults: A pilot randomized clinical trial. *Mindfulness*, 8(1), 126-135.
39. **Hartwell, E.E.**, Bujarski, S., Glasner-Edwards, S., & Ray, L.A. (2015) The association of alcohol severity and sleep quality in problem alcohol users. *Alcohol and Alcoholism*, 50(5), 536-541.
40. Roche, D.J.O., Bujarski, S., **Hartwell, E.E.**, Green, R., & Ray, L.A. (2015) Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers. *Pharmacology, Biochemistry and Behavior*, 134, 92-98.
41. Bujarski, S., Roche, D., Lunny, K., Moallen, N., Courtney, K.E., Allen, V., **Hartwell, E.**, Leventhal, A., Rohrbaugh, T., & Ray, L.A. (2014) The relationship between methamphetamine and alcohol use in a community sample of methamphetamine users. *Drug and Alcohol Dependence*, 142, 127-132.
42. **Hartwell, E.E.**, Pfeiffer, J., McCauley, J., Moran, M.M., & Back, S.E. (2014) Sleep disturbances among individuals with prescription opioid dependence. *Addictive Behaviors*, 39 (10), 1537-1542.
43. Back, S.E., Killeen, T.K., Teer, A.P., **Hartwell, E.E.**, Federline, A., Beylotte, F., & Cox, E.Q. (2014). Substance use disorders and PTSD: An exploratory study of treatment preferences among military Veterans. *Addictive Behaviors*, 39 (2), 369-373.
44. **Hartwell, E. E.**, & Ray, L. A. (2013). Sex moderates stress reactivity in heavy drinkers. *Addictive Behaviors*, 38(11), 2643-2646.
45. Courtney, K.E., Ashenurst, J., Bacio, G., Moallem, N., Bujarski, S., **Hartwell, E.E.** & Ray, L.A. (2013) Subjective responses to alcohol and alcohol craving: Validation of the desires for alcohol questionnaire in the human lab. *Journal of Studies on Alcohol & Drugs*, 74(5), 797-802.

\*Denotes co-first author; †Denotes trainee; ‡Denotes senior author

---

## PREPRINTS

---

Khan Y.,\* Davis, C.N.,\* Jinwala, Z., Feuer, K., Toikumo, S., **Hartwell, E.E.**, Sanchez-Roige, S., Peterson, R.E., Hatoum, A.S., Kranzler, H.R., Kember, R.L. (2024) [Combining Transdiagnostic and Disorder-Level GWAS Enhances Precision of Psychiatric Genetic Risk Profiles in a Multi-Ancestry Sample | medRxiv](#)

Davis, C., Jinwala, Z., Hatoum, A.S., Toikumo, S., **Hartwell, E.E.**, Agrawal, A., Edenberg,

H.J., Baurley, J.W., Rentsch, C.T., Crist, R.C., Gray, J.C., Justice, A., Gelernter, J., Kember, R.L., Kranzler, H.R. (2024) [Candidate Genes from an FDA-Approved Algorithm Fail to Predict Opioid Use Disorder Risk in Over 450,000 Veterans | medRxiv](#)

---

#### MANUSCRIPTS UNDER REVIEW, IN REVISIONS

---

46. Khan Y.,\* Davis, C.N.,\* Jinwala, Z., Feuer, K., Toikumo, S., **Hartwell, E.E.**, Sanchez-Roige, S., Peterson, R.E., Hatoum, A.S., Kranzler, H.R., Kember, R.L. (under review) Combining transdiagnostic and disorder-level GWAS enhances precision of psychiatric genetic risk profiles in a multi-ancestry sample
47. Davis, C., Jinwala, Z., Hatoum, A.S., Toikumo, S., **Hartwell, E.E.**, Agrawal, A., Edenberg, H.J., Baurley, J.W., Rentsch, C.T., Crist, R.C., Gray, J.C., Justice, A., Gelernter, J., Kember, R.L., Kranzler, H.R. (under review) Candidate genes from an FDA-approved algorithm fail to predict opioid use disorder risk in over 450,000 Veterans.
48. Uppuluri, S., Jinwala, Z., Gelernter, J., Kranzler, H.R., **Hartwell, E.E.**,<sup>†</sup> Kember, R.L.<sup>+</sup> (under review) Characterizing the role of the environment and gene by environment interactions in substance use disorders.
49. Jinwala Z., Kember R.L., Green R., Khan Y.,<sup>†</sup> **Hartwell E.E.**<sup>+</sup> (under review) Predicting treatment-seeking status for alcohol use disorder using polygenic scores and machine learning in a deeply phenotyped sample

\*Denotes co-first author; <sup>†</sup>Denotes trainee; <sup>+</sup>Denotes senior/co-senior author

---

#### OTHER PUBLICATIONS

---

##### Commentaries, Letters, and Editorials

1. Kranzler, H.R., & **Hartwell, E.E.** (2022) Treating alcohol use disorder with hallucinogens: Renewed interest after a 50-year hiatus. *JAMA Psychiatry*, 79(10), 945-946.

##### Book Chapters

2. Kranzler, H.R., Knapp, C., & **Hartwell, E.E.** (under review) Pharmacotherapy for Alcohol Use Disorders. *Clinical Manual of Addiction Psychopharmacology*, 3<sup>rd</sup> ed., Washington, DC: American Psychiatric Press, Inc.
3. Ray, L.A., **Hartwell, E.E.**, Green, R., & Venegas, A. (2019) State-of-the-art treatment of alcohol use disorder. In I. Danovitch and L. Mooney (Eds.), *The Assessment and Treatment of Addiction: Best Practices and New Frontiers* (pp. 123-136). St. Louis, MO: Elsevier.

---

#### RESEARCH PRESENTATIONS

---

##### Invited Presentations

1. Substance use research: Genetic underpinnings and clinical applications (May 2024) Psychiatry Faculty Research Seminar, University of Pennsylvania, Philadelphia, PA.
2. Current findings and applications of polygenic scores in substance use disorder research (January 2024) Behavioral Health Grand Rounds, CMCVAMC, Philadelphia, PA.

3. Implications for comorbidity and predicting risk using polygenic scores in substance use disorder research (November 2023) Clinical Neurosciences Training Seminar, UPenn, Philadelphia, PA.
4. Polygenic risk scores and substance use disorder research: Current findings and applications (September 2023) Penn Mental Health AIDS Research Center, Philadelphia, PA.
5. State of psychedelics and substance use disorder treatment (July 2023) Philadelic Conference, Philadelphia, PA.
6. Genetic architecture of substance use and depression: CDA beginnings. (May 2023) VA Research Day, Philadelphia, PA.
7. Craving in non-treatment seeking alcohol users: Clinical considerations (2018) NIAAA, Bethesda, MD.

### Symposium and Workshops

1. Discussant at "Polygenic approaches to understand alcohol use disorder: Insights from the Collaborative Study on the Genetics of Alcoholism" symposium (2024) Research Society on Alcohol, Minneapolis, MN.
2. **Hartwell, E.E.**, Kranzler, H.R., Feinn, R., Xu, H., Ho, B.L.<sup>†</sup>, Saini, D.<sup>†</sup>, Nicastro, O.<sup>†</sup>, Jacoby, A.<sup>†</sup>, Toikumo, S., Gelernter, J., & Kember, R.L. (2023) Polygenic risk for substance-related traits predicts substance use onset and progression: Sex and population group differences. Research Society on Alcohol, Bellevue, WA.
3. **Hartwell, E.E.**, Xu, H., Toikumo, S., Gelernter, J., Kranzler, H.R., & Kember, R.L. (2022) Performance of alcohol use disorder polygenic risk score in electronic health record- and cross sectional-based datasets. Research Society on Alcoholism, Orlando, FL.
4. Kember, R.L., **Hartwell, E.E.**, Xu, H., Toikumo, S., Gelernter, J., & Kranzler, H.R. (2022) Characterizing the phenotypic spectrum associated with genetic liability for alcohol-related traits. Research Society on Alcoholism, Orlando, FL.
5. Kranzler, H.R., Xu, H., Toikumo, S., Deak, J., **Hartwell, E.E.**, Zhou, H., Kampman, K., Gelernter, J., & Kember, R.L. (2022) A multi-trait genome-wide association study of problematic use. Research Society on Alcoholism, Orlando, FL.
6. **Hartwell, E.E.**, Feinn, R., Morris, P., Gelernter, J., Krystal, J., Arias, A.J., Oslin, D., Schacht, J.P., Hoffman, M., Petrakis, I., Gueorguieva, R., Anton, R.F., & Kranzler, H. (2021) A meta-analysis of the moderating effect of rs1799971 in *OPRM1*, the mu-opioid receptor gene, on naltrexone treatment of alcohol use disorder. Research Society on Alcoholism, virtual.
7. Kranzler, H.R., Morris, P.E., Pond, T., Crist, R., Kampman, K.M., **Hartwell, E.E.**, Lynch, K. (2021) Prospective pharmacogenetic study of topiramate for treating alcohol use disorder. Research Society on Alcoholism, virtual.
8. **Hartwell, E.E.**, Karno, M., & Ray, L.A. (2017) Brief motivational intervention for alcohol use disorder: Scientific rationale, empirical evidence, and hands-on training for practicing psychiatrists. American Academy of Addiction Psychiatry, San Diego, CA.

### Oral Presentations



1. **Hartwell, E.E.** (September 2024) Genetic architecture of alcohol use disorder: Role of depression. MIRECC Investigator Forum, Crescenz VA, Philadelphia, PA.
2. Davis, C.N., Feinn, R., Jinwala, Z., Khan, Y., Oikonomou, A., Silva-Lopez, D., Burton, I., Dixon, M., Milone, J., Ramirez, S., Shifman, N., Levey, D.F., Gelernter, J., **Hartwell, E.E.**, Kember, R.L., Kranzler, H.R. (June 2024) Adverse childhood events, mood and anxiety disorders, and substance dependence: Gene x environment effects and moderated mediation. Research Society on Alcohol, Minneapolis, MN.
3. Toikumo, S., Vickers-Smith, R.A., Jinwala, Z., Zu, H., Saini, D., **Hartwell, E.E.**, Venegas, M.V.P., Sullivan, K., Xu, K., Jacobson, D.A., Gelernter, J., Rentsch, C.T., Stahl, E., Cheatle, M., Zhou, H.T., Waxman, S., Justice, A.C., Kember, R.L., & Kranzler, H.R. (October 2023) The genetic architecture of pain intensity in a sample of 598,339 US Veterans. World Congress of Psychiatric Genetics, Montreal, Canada.
4. **Hartwell, E.E.** (February 2023) Use of phenome-wide association studies to investigate genetic liability for substance use and related disorders. Center for Studies on Addiction, UPenn, Philadelphia, PA.
5. **Hartwell, E.E.** (December 2022) Investigating genetic architecture and liability of substance use disorders and their comorbidities. MIRECC Investigator Forum, Crescenz VA, Philadelphia, PA.
6. **Hartwell, E.E.**, Kranzler, H.R., Kember, R.L. (December 2022) Comparing Phenome-wide Association Studies of Alcohol Use Disorder Polygenic Risk Score in an Electronic Health Record Biobank and Deeply Phenotyped Sample. Million Veteran Program Science Meeting, St. Petersburg, FL.
7. **Hartwell, E.E.**, Merikangas, A., Verma, S., Ritchie, M., Regeneron Genetics Center, Kranzler, H.R., & Kember, R.L. (October 2021) Differences in phenotypic associations of genetic liability for substance use by ancestry and sex. World Congress of Psychiatric Genetics (virtual).
8. Kember, R.L., Vickers-Smith, R., Zhou, H., Toikumo, S., Rentsch, C., Zhou, H., **Hartwell, E.E.**, Crist, R.C., Justice, A., Kampman, K.M., Gelernter, J., Kranzler, H.R. (October 2021) Cross-ancestry meta-analysis of OUD uncovers novel associated loci. World Congress of Psychiatric Genetics (virtual).
9. Kember, R.L., **Hartwell, E.E.**, Merikangas, A.K., Verma, S.S., Verma, A., Damrauer, S., Rader, D., Ritchie, M., Regeneron Genetics Center, & Kranzler, H.R. (October 2020) Genetic liability for substance use associated with medical comorbidities in electronic health records for African and European ancestry individuals. World Congress of Psychiatric Genetics (virtual).
10. Kranzler, H.R., Love, T., Shabalin, A., Kember, R., Docherty, A., Zhao, H., Gelernter, J., Dubroff, J., **Hartwell, E.**, Zubieta, J-K. (September 2020) Opioid use disorder polygenic risk score correlates with brain mu-opioid receptor drug reward circuitry. Million Veteran Program annual conference (virtual).
11. **Hartwell, E.E.**, & Kranzler, H.R. (2019) Meta-analyses of alcohol use disorder pharmacotherapy. MIRECC Investigator Forum, Philadelphia, PA.
12. **Hartwell, E.E.**, & Ray, L.A. (2015) Gender differences in craving and internalizing symptoms in methamphetamine dependence. College on Problems of Drug Dependence meeting, Phoenix, AZ.
13. **Hartwell, E.E.**, & Ray, L.A. (2015) Genetic and environmental determinants of drug abuse. Drug Abuse Research Day, Drew University, Los Angeles, CA.
14. **Hartwell, E.E.**, & Ray, L.A. (2014) Pharmacogenetics of naltrexone and varenicline in heavy drinking smokers. PsychFest Symposium, UCLA, Los Angeles, CA.

15. **Hartwell, E.E.**, Lawson, K., Singleton, L., & Back, S.E. (2010) Gender differences in presenting characteristics and severity of substance use among individuals with prescription opioid dependence. College on Problems of Drug Dependence, Scottsdale, AZ.

#### *Poster Presentations*

1. Davis, C.,<sup>†</sup> Jinwala, Z., Hatoum, A.S., Toikumo, S., <sup>†</sup> **Hartwell, E.E.**, Agrawal, A., Edenberg, H.J., Baurley, J.W., Rentsch, C.T., Crist, R.C., Gray, J.C., Justice, A., Gelernter, J., Kember, R.L., Kranzler, H.R. (submitted to 2025 NIDA Genetics Meeting) Candidate genes from an FDA-approved algorithm fail to predict opioid use disorder risk in over 450,000 Veterans
2. Khan, Y.,<sup>†</sup> Davis, C.N.,<sup>†</sup> Crist, R.C., Vickers-Smith, R., **Hartwell, E.E.**, Gelernter, J.G., Kember, R.L., Laffont C.M., & Kranzler, H.R. (2025) Multi-ancestry genome-wide association meta-analysis of buprenorphine treatment response. Lifespan Brain Institute Symposium, Philadelphia, PA.
3. **Hartwell, E.E.**, Jinwala, Z., Voight, B., Oslin, D., Gelernter, J., Kranzler, H.R., Kember, R.L. (accepted for presentation, 2024) Multi-ancestry stratified GWAS of alcohol use disorder and comorbid depression identifies novel loci. American Society of Human Genetics, Denver, CO.
4. Khan, Y.,<sup>†</sup> Davis, C.N.,<sup>†</sup> Jinwala, Z., Feurer, K.,<sup>†</sup> Toikumo, S.,<sup>†</sup> **Hartwell, E.E.**, Peterson, R.E., Hatoum, A.S., Kranzler, H.R., Kember, R.L. (2024) Using gSEM to evaluate common and independent genetic factors that underlie substance use, psychotic, mood, and anxiety disorders. Behavioral Genetics Association, London, U.K.
5. Khan, Y.,<sup>†</sup> Davis, C.N.,<sup>†</sup> Jinwala, Z., Feurer, K.,<sup>†</sup> Toikumo, S.,<sup>†</sup> **Hartwell, E.E.**, Peterson, R.E., Hatoum, A.S., Kranzler, H.R., Kember, R.L. (2024) Using gSEM to evaluate common and independent genetic factors that underlie substance use, psychotic, mood, and anxiety disorders. Research Society of Alcohol, Minneapolis, MN.
6. Jinwala, Z., Kember, R.L., Green, R., Khan, Y.,<sup>†</sup> Gelernter, J., Kranzler, H.R., **Hartwell, E.E.** (June 2024) Predicting treatment seeking for alcohol use disorder using polygenic scores and machine learning. Research Society of Alcohol, Minneapolis, MN.
7. **Hartwell, E.E.**, Jinwala, Z., Gelernter, J., Kranzler, H.R., Kember, R.L. (June 2024) Polygenic scores for psychiatric traits are associated with substance use phenotypes in a deeply phenotyped sample. College on Problems of Drug Dependence, Montreal, Canada.
8. **Hartwell, E.E.**, Jinwala, Z., Milone, J.,<sup>†</sup> Ramirez, S.,<sup>†</sup> Gelernter, J., Kranzler, H.R., Kember, R.L. (April 2024) Polygenic scores for psychiatric and medical traits provide insights into underlying pleiotropy in a deeply phenotyped sample enriched for substance use disorders. Department of Genetics annual symposium, University of Pennsylvania, Philadelphia, PA.
9. Jinwala, Z., Khan, Y.,<sup>†</sup> Kember, R.L., Gelernter, J., Kranzler, H.R., **Hartwell, E.E.** (October 2023) Predicting treatment seeking status using machine learning in a deeply phenotyped sample: Incorporating PRS. CHOP/Penn MidAtlantic Bioinformatics Conferences, Philadelphia, PA.
10. Toikumo, S.,<sup>†</sup> Vickers-Smith, R.A., Jinwala, Z., Zu, H., Saini, D., **Hartwell, E.E.**, Venegas, M.V.P., Sullivan, K., Xu, K., Jacobson, D.A., Gelernter, J., Rentsch, C.T., Stahl, E., Cheattle, M., Zhou, H.T., Waxman, S., Justice, A.C., Kember, R.L., & Kranzler, H.R. (2023) The genetic architecture of pain intensity in a sample of 598,339 US Veterans. American Society of Human Genetics, Washington, D.C.

11. Toikumo, S.<sup>†</sup>, Vickers-Smith, R.A., Jinwala, Z., Zu, H., Saini, D., **Hartwell, E.E.**, Venegas, M.V.P., Sullivan, K., Xu, K., Jacobson, D.A., Gelernter, J., Rentsch, C.T., Stahl, E., Cheatle, M., Zhou, H.T., Waxman, S., Justice, A.C., Kember, R.L., & Kranzler, H.R. (October 2023) The genetic architecture of pain intensity in a sample of 598,339 US Veterans. Million Veteran Program meeting, Washington, D.C.
12. Dubroff, J.G., Hsieh, C.-J., Wetherill, R.R., Wiers, C.E., **Hartwell, E.E.**, Lee, H., Mach, R., & Kranzler, H.R. (2023) Whole-body dynamic imaging of mu-opioid receptors, a first-in-human study of [C-11] carfentanil PET imaging using the PennPET Explorer instrument. Society of Nuclear Medicine and Molecular Imaging meeting.
13. **Hartwell, E.E.**, Kember, R.L., Jinwala, Z., Gelernter, J., Kranzler, H.R. (June 2023) Polygenic risk score for major depression predicts multiple alcohol-related phenotypes in a deeply phenotyped sample. Research Society on Alcohol meeting, Bellevue, WA.
14. Toikumo, S.<sup>†</sup>, Vickers-Smith, R.A., Jinwala, Z., Zu, H., Saini, D., **Hartwell, E.E.**, Venegas, M.V.P., Sullivan, K., Xu, K., Jacobson, D.A., Gelernter, J., Rentsch, C.T., Stahl, E., Cheatle, M., Zhou, H.T., Waxman, S., Justice, A.C., Kember, R.L., & Kranzler, H.R. (May 2023) The genetic architecture of pain intensity in a sample of 598,339 US Veterans. VA Research Day, Philadelphia, PA.
15. **Hartwell, E.E.**, Kember, R.L., Jinwala, Z., Gelernter, J., Kranzler, H.R. (May 2023) Performance of a polygenic risk score for major depression in a deeply phenotyped sample. NIDA Genetics and Epigenetics Meeting, Washington, DC.
16. Kember, R.L., **Hartwell, E.E.**, Xu, H., Toikumo, S., Gelernter, J., & Kranzler, H.R. (September 2022) Characterizing the phenotypic spectrum associated with genetic liability for alcohol-related traits. World Congress on Psychiatric Genetics, Florence, Italy.
17. Toikumo, S., Xu, H., **Hartwell, E.E.**, Kember, R.L., & Kranzler, H.R. (June 2022) Integrating human brain proteomes with genome-wide association results identifies new brain proteins for alcohol and other substance use traits. Research Society on Alcoholism, Orlando, FL.
18. Kranzler, H.R., Kember, R.L., Vickers-Smith, R., Zhou, H., Toikumo, S., Rentsch, C., Zhou, H., **Hartwell, E.E.**, Crist, R.C., Justice, A., Kampman, K.M., Gelernter, J. (December 2021) Cross-ancestry meta-analysis of opioid use disorder uncovers novel associated loci. American College of Neuropsychopharmacology, Puerto Rico.
19. Love, T., Shabalín, A., Kember, R., Docherty, A., Zhao, H., Gelernter, J., Dubroff, J., **Hartwell, E.**, Zubieta, J.-K., & Kranzler, H.R. (December 2021) Opioid use disorder polygenic risk score correlates with brain mu-opioid receptor drug reward circuitry. American College of Neuropsychopharmacology, Puerto Rico.
20. **Hartwell, E.E.**, Merikangas, A., Verma, S., Ritchie, M., Regeneron Genetics Center, Kranzler, H.R., & Kember, R.L. (September 2021) Genetic liability for substance use associated with medical comorbidities in electronic health records of African- and European-ancestry individuals. Million Veteran Program, virtual.
21. Crist, R.C., Vicker-Smith, R., Kember, R.L., Rentsch, C.T., Edelman, E.J., **Hartwell, E.E.**, Kampman, K., Kranzler, H.R. (September 2021) Buprenorphine dosing and treatment outcomes in Veterans with opioid use disorder. Are associated with race and ethnicity. Million Veteran Program, virtual.

22. Crist, R.C., Vickers-Smith, R., Kember, R.L., Rentsch, C.T., **Hartwell, E.E.**, Edelman, J., Kampman, K.M., & Kranzler, H.R. (June 2021) Treatment outcomes differ by race and ethnicity among buprenorphine-treated Veterans in MVP. College on Problems of Drug Dependence, Quebec/virtual.
23. Crist, R.C., Vickers-Smith, R., Kember, R.L., Rentsch, C.T., **Hartwell, E.E.**, Edelman, J., Kampman, K.M., & Kranzler, H.R. (September 2020) Developing phenotypes to assess treatment effectiveness in Veterans receiving buprenorphine for opioid use disorder. Million Veteran Program, Virtual.
24. **Hartwell, E.E.**, Feinn, R., Morris, P.M., & Kranzler, H.R. (September 2019) A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Philadelphia Psychiatric Society Addiction Symposium, Philadelphia, PA.
25. **Hartwell, E.E.**, Feinn, R., Morris, P.M., & Kranzler, H.R. (June 2019) A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Research Society on Alcoholism, Minneapolis, MN.
26. **Hartwell, E.E.**, & Ray, L.A. (June 2018) Genetic markers of alpha-Synuclein and their relationship with alcohol craving. Research Society on Alcoholism, San Diego, CA.
27. **Hartwell, E.E.**, Green, R., & Ray, L.A. (June 2017) Performance of craving as a DSM-5 alcohol use disorder symptom in non-treatment seekers. Research Society on Alcoholism, Denver, CO.
28. Roche, D.J.O., Bujarski, S., Green, R., **Hartwell, E.E.**, & Ray, L.A. (June 2017) Alcohol and tobacco consumption is associated with increased odds of same day marijuana use. Research Society on Alcoholism meeting, Denver, CO.
29. **Hartwell, E.E.**, Green, R., MacKillop, J. & Ray, L.A. (March 2017) Behavioral economics of varenicline and naltrexone in heavy drinking smokers. Society for Research on Nicotine and Tobacco, Florence, Italy.
30. **Hartwell, E.E.**, & Ray, L.A. (June 2016) Relationship of tonic craving and urges to drink during alcohol cue exposure. Research Society on Alcoholism, New Orleans, LA.
31. **Hartwell, E.E.**, & Ray, L.A. (June 2016) Differences in clinical presentation between high and low impulsive methamphetamine users. College on Problems of Drug Dependence, Palm Springs, CA.
32. Sanchez, V.,<sup>†</sup> **Hartwell, E.E.**, & Ray, L.A. (May 2016) Relationship between ADHD symptoms and methamphetamine use. Psychology Undergraduate Research Conference, Los Angeles, CA.
33. Yardley, M., **Hartwell, E.**, Roche, D., Bujarski, S., & Ray, L. (December 2015) Differences between treatment and non-treatment seeking alcoholics: Do they matter? American College on Neuropsychopharmacology, Hollywood, FL.
34. **Hartwell, E.E.**, McRae-Clarke, A.L., Ray, L.A., Brady, K.T., & Hartwell, K.J. (December 2015) Differences between urban and rural individuals with methamphetamine dependence. American Academy of Addiction Psychiatry, Huntington Beach, CA.
35. **Hartwell, E.E.**, Bujarski, S., Glasner-Edwards, S., & Ray, L.A. (June 2015) The association of sleep quality with alcohol severity and liver function in problem alcohol users. Research Society on Alcoholism, San Antonio, TX.
36. Glasner-Edwards, S., Mooney, L.J., Ang, A., Chokron Garneau, H., **Hartwell, E.E.**, Brecht, M.L., & Rawson, R.A. (June 2015) Mindfulness-based relapse prevention improves stimulant use among

stimulant dependent adults with major depression and generalized anxiety disorder. College on Problems of Drug Dependence, Phoenix, AZ.

37. **Hartwell, E.E.**, Ray, L.A., Chokron Garneau, H., Brecht, M.L., & Glasner-Edwards, S. (November 2014) Changes in stress reactivity among stimulant users in response to a mindfulness-based intervention. Association of Behavioral and Cognitive Therapies, Philadelphia, PA.
38. **Hartwell, E.E.**, Roche, D.J., & Ray, L.A. (June 2014) Pharmacogenetics of naltrexone and varenicline in heavy drinking smokers. Research Society on Alcoholism, Seattle, WA.
39. **Hartwell, E.E.**, & Ray, L.A. (June 2013) Gender moderates stress reactivity in heavy drinkers. Research Society on Alcoholism, Orlando, FL.
40. Mercer, M.A., **Hartwell, E.E.**, Brady, K.T., & Back, S.E. (January 2013) Sleep quality, stress and drug cue reactivity among prescription opioid dependent individuals. Addiction Medicine Retreat, MUSC, Charleston, SC.
41. **Hartwell, E.E.**, Brady, K.T., & Back, S.E. (August 2012) Sleep disturbances among individuals with prescription opioid dependence. American Psychological Association, Orlando, FL.
42. **Hartwell, E.E.**, Brady, K.T., & Back, S.E. (June 2012) Sleep quality and stress reactivity among individuals with prescription opioid dependence. College on Problems of Drug Dependence, Palm Springs, CA.
43. Leger, J.E., Book, S.W., & **Hartwell, E.E.** (September 2011) The influence of social anxiety on readiness to change in drug and alcohol addiction outpatient rehabilitation. Drug Abuse Research Training (DART) Summer Fellowship Symposium, MUSC, Charleston, SC.
44. **Hartwell, E.E.**, Eaddy, J., Singleton, L., Brady, K.T., & Back, S.E. (August 2011) Development of a drug cue paradigm for prescription opioids. American Psychological Association, Washington, D.C.
45. **Hartwell, E.E.**, Book, S.W., Randall, C.L., McGuan, E.B., Miller, P.M., Randall, P.K., Smith, J.P., Bernstein, G., Kushner, M.G., Maurer, E., Specker, S., & Thomas, S.E. (June 2011) Prevalence and importance of smoking to self-medicate social fears in socially anxious individuals who also use alcohol to cope: A gender analysis. Research Society on Alcoholism, Atlanta, GA.
46. **Hartwell, E.E.**, Back, S.E., & Brady, K.T. (June 2011) Impaired sleep functioning in prescription opioid-dependent individuals. College on Problems of Drug Dependence, Hollywood, FL.
47. Lawson, K., Singleton, L., **Hartwell, E.E.**, Brady, K.T., & Back, S.E. (June 2010) Gender differences in motives to use and sources of prescription opioids. College on Problems of Drug Dependence, Scottsdale, AZ.
48. Singleton, L., Lawson, K., **Hartwell, E.E.**, & Back, S.E. (May 2010) Gender and prescription opiates: A preliminary examination of motives and sources. Conference for Student Research on Addictions, Infectious Disease, and Public Health, Johns Hopkins University, Baltimore, MD.
49. **Hartwell, E.E.**, Lawson, K., Singleton, L., & Back, S.E. (May 2010) Gender differences in presenting characteristics and severity of substance use among individuals with prescription opioid dependence. Conference for Student Research on Addictions, Infectious Disease, and Public Health, Johns Hopkins University, Baltimore, MD.

†Denotes trainee

---

## RESEARCH EXPERIENCE

---

- 2012-2018 Graduate Research Assistant**  
*Addictions Lab, Department of Psychology, UCLA. PI: Dr. Lara Ray*
- 2011-2012 Senior Research Assistant**  
*Alcohol Research Center, Department of Psychiatry and Behavioral Sciences, MUSC. Principal Investigators: Drs. Carla Kmett Danielson & Suzanne Thomas*
- 2010-2011 Research Assistant**  
*Center for Drug and Alcohol Programs, Department of Psychiatry and Behavioral Sciences, MUSC. Principal Investigators: Drs. Carrie Randall & Sarah Book*
- 2009-2010 Research Fellow**  
*Clinical Neuroscience Division, Department of Psychiatry and Behavioral Sciences, MUSC. Principal Investigator: Dr. Sudie Back*

---

## CLINICAL TRAINING

---

- 2018-2021 **Psychology Fellow**, *Philadelphia VA Medical Center*  
Clinical Rotations: Addiction Recovery Unit and Inpatient Psychiatry Unit  
Supervisors: Drs. Kristin Taylor and Anna Fineberg
- 2017-2018 **Psychology Intern**, *West Los Angeles VA*  
Clinical Rotations: Ambulatory Care, Addictive Behaviors Clinic, Health Psychology, Domiciliary, H-PACT  
Supervisors: Drs. Anna Okonek, Donna Ames, Christopher Jetton, Greg Serpa, Joanna Rowles, Peter Graves, Jesse Barglow, Naomi Himmelfarb, Morgan Kay
- 2012-2018 **Research Therapist**, *UCLA Addictions Lab*  
Supervisor: Lara Ray, PhD
- 2015-2017 **Advanced Student Therapist**, *Substance Abuse & Health Track, UCLA Psychology Clinic*  
Supervisor: Grace Rosales, PhD
- 2015-2017 **SBIRT Research Therapist**, *Integrated Substance Abuse Programs, UCLA*  
Supervisors: Drs. Mitch Karno & Suzette Glasner-Edwards
- 2014-2015 **Practicum Student Therapist**, *Counseling and Psychological Services, UCLA*  
Supervisors: Shauna McManus, PsyD & Lisa Christensen, PhD
- 2013-2014 **Student Therapist and Assessor**, *UCLA Psychology Clinic, UCLA*  
Supervisors: Drs. Danielle Keenan-Miller, Jill Waterman, & Denise Chavira
- 2010-2012 **Research Assessor**, *Center for Drug & Alcohol Programs, MUSC*  
Supervisors: Drs. Carla Danielson & Sudie Back

---

## SELECTED PROFESSIONAL TRAININGS

---

Contingency Management for Substance Use Disorders (2020)  
Instructor: Dominick DePhilippis, PhD

Precision Medicine Frontiers (2019)  
Instructor: David Fagenbaum, MD

Genetics of Addiction (2018)  
Instructors: Jackson Laboratory and guest faculty

Psychopharmacology for Psychologists (2018)  
Instructors: Drs. Arkady Korotinsky, Donna Ames, Brandon Yarns, David Sultzer

Suicide Assessment and Prevention for Veterans (2017)  
Instructor: Sharon Birman, PsyD

---

## TEACHING EXPERIENCE

---

### Mentoring

Olivia Nicastro, University of Pennsylvania, Senior thesis (Primary advisor, 2024-2025)  
Sindhujaa Uppuluri, University of Pennsylvania, Senior thesis (Co-advisor, 2023-2024)  
Jackson Milone, University of Pennsylvania, Summer ITMAT student (Primary advisor, 2023)  
Sarah Ramirez, University of Pennsylvania, Summer ITMAT student (Co-advisor, 2023)

### Committees

Anna Leonard, Candidacy exam committee member (PI: Julie Blendy), May 2024

### Guest Lectures

Addiction Psychiatry Fellowship Didactic Series, "Critical consumption of medical research,"  
RJVAMC/MUSC (September 2024)

Project ECHO, "Update on the role of genetics and addiction," MUSC (July 2024)

Peers ECHO, "Motivational Interviewing: Back to the basics," MUSC (April 2024)

Addiction Psychiatry Fellowship Didactic Series, "Motivational interviewing for alcohol use disorders,"  
CMCVAMC/University of Pennsylvania Fellowship Training (April 2019, February 2022, September  
2022, February 2024)

Psychology Internship Didactic Series, "Motivational interviewing for alcohol use disorders," University of  
Pennsylvania (April 2023, November 2023, August 2024)

Peers ECHO, "Psychedelics and substance use treatment: State of the field," MUSC (September 2023)

Project ECHO, "CBT principles for prescribers," MUSC (July 2023)

Peers ECHO, "Motivational interviewing: Providing feedback and offering advice," MUSC (April 2023)

Center for Studies on Addition Summer Seminar Series, "Psychosocial treatments for substance use  
disorders" (July 2022, June 2023, July 2024) University of Pennsylvania

Addiction Fellowship Seminar, "Understanding Meta-Analysis," MUSC (March 2019, September 2019,  
March 2021, March 2023)

Addiction Fellowship Seminar, "Motivational interviewing for alcohol use disorders," UCLA/West Los Angeles VA Residency Training (January 2018)

Foundations of Clinical Psychology, "Brief interventions for substance use disorders", UCLA Psych 270A (July 2016, May 2017)

Foundations of Clinical Psychology, "Assessment and diagnosis of substance use disorders," UCLA Psych 270C (July 2016, May 2017)

Abnormal Psychology, "Substance use disorders," UCLA Psych 127A (July 2016)

Psychology of Addiction, "Psychosocial treatments for addiction," UCLA Psych 162 (May 2016, July 2016, July 2017)

Fieldwork in Psychology, "Substance use disorders: Prevalence, assessment, and treatment," UCLA Psych 194A (May 2014, February 2015)

*Teaching Assistant*

Spring 2017 **Fieldwork in Psychology** (UCLA, Psych 194A)

Responsibilities: Provide supervision to undergraduate students who are completing psychology internships, write syllabus, grade reflection papers, organize guest lectures.

Fall 2016 **Research Methods** (UCLA, Psychology 100B)

Responsibilities: Teach psychological research methods using in-class experiments and writing assignments.

Summer 2016 **Abnormal Psychology** (UCLA, Psychology 127A)

Responsibilities: Administration and scoring of examinations, lead review sessions, grade papers.

Winter 2016 **Fieldwork in Psychology** (UCLA, Psych 194A)

Responsibilities: Provide supervision to undergraduate students who are completing psychology internships, write syllabus, grade reflection papers, organize guest lectures.

Spring 2015 **Psychology of Addiction** (UCLA, Psych 162)

Responsibilities: Administration and scoring of examinations, lead review sessions, prepare test questions.

Spring 2014 **Biological Bases of Abnormal Behavior** (UCLA, Psych 127B)

Responsibilities: Administration and scoring of examinations, lead review sessions, prepare test questions, grade manuscript reviews.

---

MEMBERSHIPS & AFFILIATIONS

---

American Society of Human Genetics

Early career member, 2024-present

International Society for Biomedical Research on Alcoholism

Early career investigator, 2023-present

Post-doctoral member, 2020-2022

Research Society on Alcohol

Regular member, 2023-present

Post-doctoral member, 2019-2022



International Society of Psychiatric Genetics  
Post-doctoral member, 2021-2023  
American Academy of Addiction Psychiatry  
Student member, 2017-2019  
American Psychological Association  
Student member, 2013-2016  
College on Problems of Drug Dependence  
Regular member, 2022-present  
Member-In-Training, 2010-2022

---

## SERVICE

---

### Grant Reviews

08/2023      Research Triangle Institute, PASA  
08/2022      Research Triangle Institute, PASA

### Educational Activities

Member, Neuroscience Graduate Group, University of Pennsylvania 2023-present  
Associate member, Institute for Translational Medicine and Therapeutics, University of Pennsylvania 2022-present

### Committees

Member, Program Committee, Research Society on Alcohol 2025 annual meeting  
Member, Admissions Committee, University of Pennsylvania School of Medicine, 2024-2025  
Chair, Data Safety and Monitoring Board, Center for Studies on Addiction, June 2024-present  
Member, Travel Awards Committee, College on Problems of Drug Dependence, June 2024-present  
Member, Anna T. Meadows Society for Clinician Educators, University of Pennsylvania, Mentoring committee 2024-present  
Member, Travel Award Committee, Sex and Gender and Alcohol Sattelite Meeting at RSA, 2024  
Member, Program Committee, Research Society on Alcoholism 2023 annual meeting  
Member, Faculty Advisory Committee, Philadelic Consortium, 2022-present

### Journal Editorial Service

Field Editor, *Alcohol: Clinical and Experimental Research*, 2/2023-present  
Review Editor, *Frontiers in Psychiatry* (Addictive Disorders section), 9/2022-present

### Ad-hoc Journal Reviews

*Addiction*, 2018-present  
*Addiction Neuroscience*, 2023  
*Addictive Behaviors*, 2013-present  
*Addictive Behaviors Reports*, 2024  
*Alcohol*, 2022-present  
*Alcohol & Alcoholism*, 2016-2018  
*Alcohol: Clinical and Experimental Research*, 2016-present  
*BMC Medicine*, 2024  
*Expert Review of Precision Medicine and Drug Development*, 2019  
*Expert Opinion on Emerging Drugs*, 2024  
*Expert Opinion on Pharmacotherapy*, 2024  
*Frontiers in Psychology*, 2024  
*Frontiers in Psychiatry*, 2022-present  
*Health and Quality of Life Outcomes*, 2024  
*Journal of Addiction Medicine*, 2023-present

*Journal of Dual Diagnosis*, 2022  
*Journal of Psychoactive Drugs*, 2019  
*Journal of Psychopathology and Behavioral Assessment*, 2019-2020  
*Journal of Substance Abuse Treatment*, 2017-2021  
*Nature Communications*, 2024  
*Pharmacology, Biochemistry and Behavior*, 2019  
*PlosOne*, 2020  
*Psychiatry and Clinical Neurosciences*, 2018  
*Psychology of Addictive Behaviors*, 2019